Drug Approval | November 30, 2022
AstraZeneca’s Dapagliflozin receives CDSCO approval
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
40,000 visitors and representatives of more than 80 countries set to visit the show
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
The only definitive way to diagnose and stage lung cancers is through biopsies
The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The company will reduce wastage substantially, increase productivity, enhance environmental consciousness, save energy, optimally use natural resources, and expand its market penetration
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Subscribe To Our Newsletter & Stay Updated
